Hanall Biopharma Co., Ltd.
009420.KS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.91T
Close$
$1703.01
95.7% downside
Current Fair Value
95.7% downsideOvervalued by 95.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.91 Trillion |
|---|---|
| Enterprise Value | $1.92 Trillion |
| Earnings per Share | $-111.55 |
| Beta | 0.88 |
| Outstanding Shares | 52,241,000 |
Return
| Return on Equity | -13.70% |
|---|---|
| Return on Assets | -9.21% |
| Return on Invested Capital | -8.96% |
Valuation & Multiples
| P/E Ratio | -87.32 |
|---|---|
| PEG | -9.45 |
| Price to Sales | 12.74 |
| Price to Book Ratio | 12.75 |
| Enterprise Value to Revenue | 11.89 |
| Enterprise Value to EBIT | -120.4 |
| Enterprise Value to Net Income | -87 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
$54.40
Consensus analyst estimateRevenue Estimate
$24.00 B
Consensus analyst estimateNext Earnings Call
Expected Date
January 20, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$24.00 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hanall Biopharma Co., Ltd.
315 employees
CEO: Su-Jin Park
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabeti...